Phaseline

Targets › RNAP

RNAP: drug programs, companies and trials

4 programs from 3 companies in 7 trials: 5 Phase 2, 1 Phase 4, 1 Phase 3; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on RNAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Huashan HospitalRifapentine
Bacterial DNA-directed RNA polymerase inhibitor
RNAPPhase 4Tuberculosis; Tuberculosis, PulmonaryNov 2027
Institute of Tropical Medicine, Belgiumrifampicin (BE-PEP)
RNA polymerase inhibitor
RNAPPhase 3LeprosyMar 2027
McGill University Health Centre/Research Institute of the McGill University Health CentreLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRB, RNAPPhase 2Tuberculosis Infection, LatentApr 2027
McGill University Health Centre/Research Institute of the McGill University Health CentreRifampin
Bacterial DNA-directed RNA polymerase inhibitor
RNAPPhase 2Tuberculosis Infection, LatentApr 2027

Conditions

Tuberculosis, Pulmonary (3) Tuberculosis Infection, Latent (2) Tuberculosis (1) Leprosy (1)

Modalities

small molecule (3)

Companies

McGill University Health Centre/Research Institute of the McGill University Health Centre (2) Huashan Hospital (1) Institute of Tropical Medicine, Belgium (1)

Related targets

GYRB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.